In the remote town of Piñas, nestled in the Andes mountains of southern Ecuador, an intriguing phenomenon has captured the attention of medical researchers. This small community is home to an unusually high number of individuals living with Laron syndrome, a rare genetic condition that stunts growth, keeping individuals shorter than 1.2 meters. What makes this even more fascinating is the potential link between Laron syndrome and a reduced risk of certain diseases, particularly cancer and diabetes.
The story of María Luísa Romero and her twin sister, María del Cisne, sheds light on the challenges and strengths that come with living with Laron syndrome. For them, support and understanding within their community have been crucial.
"We find strength in each other, and one of us always defends the other," María Luísa shares, highlighting the power of unity in facing adversity.
But what makes Laron syndrome truly remarkable is the potential it holds for medical advancements. Researchers like Dr. Jaime Guevara, an endocrinologist who has dedicated 40 years to studying this condition, believe that understanding Laron syndrome could lead to groundbreaking treatments for cancer prevention.
"The idea is to replicate, through a drug or diet, the unique biological processes seen in Laron patients, for the benefit of those without the syndrome," Dr. Guevara explains. This approach could be a significant contribution from this unique community to global health.
Laron syndrome, also known as growth hormone insensitivity, occurs when the body cannot utilize the growth hormone it produces. This genetic mutation, identified by paediatrician Zvi Laron 60 years ago, is believed to have originated in Indonesia and spread westward along ancient merchant routes.
Interestingly, the highest concentration of Laron syndrome cases is found in the southern Ecuadorian provinces of El Oro and Loja. According to Prof. Laron, Sephardic Jews with the mutation migrated to different continents, including the Americas, and settled in isolated areas, leading to a high incidence in Ecuador through generations of intermarriage.
The twins' story also highlights the psychological impact of living with a rare condition. Moving away from their supportive community to study elsewhere, they faced stares and curiosity due to their short stature.
"It was odd being in a place where no one had ever seen people like us before," María Luisa recalls.
However, their participation in Dr. Guevara's major study, which revealed a lower incidence of diseases like cancer and diabetes among Laron patients, gave them a sense of purpose and hope.
Dr. Guevara and his team, in collaboration with Dr. Valter Longo, a specialist in ageing from the University of Southern California, aimed to replicate the biological processes seen in Laron syndrome to understand its potential protective effects.
Their research involved studying over 1,700 individuals, including about 100 with Laron syndrome and 1,600 relatives of normal height from the same villages. Over 22 years, they found no cases of diabetes and only one non-fatal cancer case among Laron patients, compared to 5% diabetes and 17% cancer diagnoses in individuals of normal height.
The team attributes this to the mutation in the growth hormone receptor in the liver, which prevents Laron patients from generating Insulin-like Growth Factor 1 (IGF-1), thus halting growth at a short stature. Dr. Guevara theorizes that IGF-1 may prevent cancer cells from dying, and lower levels of IGF-1 in Laron patients could explain the reduced cancer incidence.
Prof. Laron's research in Israel also supports this potential protection against cancer, and he believes Laron syndrome could provide the foundation for future treatments.
However, the twins' story takes an unexpected turn. Despite their initial belief in their immunity to cancer, María del Cisne was diagnosed with colon cancer two years ago. This served as a wake-up call, reminding them of the importance of self-care and a healthy lifestyle.
Laron syndrome is recessive, requiring inheritance of the gene from both parents to present symptoms. The twins' children, Matías and Lucía, do not have Laron syndrome and are already taller than their mothers at eight years old.
For those with Laron syndrome, there is hope in the form of a drug called Increlex, which can increase height if administered during growth spurts. However, accessing this medication is challenging due to its high cost and limited availability, with serious side effects in some cases.
Mayra Loaiza, a resident of Piñas, faces this challenge with her two-year-old daughter, Camila, who is supposed to start treatment but has yet to receive her first dose. Mayra's concern for her daughter's well-being and desire for a normal life free from discrimination due to size highlight the ongoing struggles faced by those with Laron syndrome.
The twins, now 40, missed the window for taking Increlex, and while they wonder about the potential impact on their lives, they have learned to accept their short stature.
"We've accepted ourselves as we are, and while the treatment might have spared us some heartache, we're grateful for who we are," María Luísa reflects.
This story not only highlights the potential medical advancements that could arise from studying rare genetic disorders but also the human resilience and strength that can be found within unique communities.
